Jerums 2001

Methods	Country: Australia Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 24‐36 months Loss to follow‐up: 9
Participants	Inclusion criteria Age: 16‐65 years DM: Type 1 for at least 5 years with persistent ketonuria and weight loss on presentation Microalbuminuria: 2 or 3 measurements of albumin excretion rate between 20‐200 µg/min performed on overnight urine collections BP: Supine 160/90 mm Hg or less if 40 years or older or 140/90 mm Hg or less if > 40 years Perindopril group Number: 13 Age: 35 (5) Sex (M/F): 4/9 Placebo group Number: 10 Age: 28 (3) Sex (M/F): 7/3 Exclusion criteria Non‐diabetic renal disease Significant renal impairment (SCr > 0.2 mmol/L) Haematuria Cardiac failure Hypertension Concurrent systemic disease Poor diabetic control (HbA1c > 10%) Serum potassium > 5 mmol/L Recurrent UTI Patients at high risk for pregnancy Patients with another condition or therapy that might pose a risk to the patient or confound the results of the study
Interventions	Perindopril group 2‐8 mg/d Placebo group Co‐interventions: No
Outcomes	AER BP GFR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear